Abstract
Diethylcarbamazine (N,N-diethyl-4-methyl-1-piperazine carboxamide [DEC]) is widely used, especially in tropical regions, to prevent and treat filariasis. The antifilarial effect of this drug has been attributed to immunomodulation. Evidence is accumulating to indicate that DEC may mitigate the course of feline leukemia virus infection (FeLV) in cats. Previous studies have suggested that continuous oral DEC treatment given shortly after evidence of FeLV infection prevents or delays lymphopenia and prolongs survival. The present study focuses on the hematologic effects of one month oral DEC treatment given to adult chronically FeLV-infected cats and uninfected cats as compared to untreated FeLV-infected cats. Such treatment frequently resulted in abruptly lowered peripheral lymphocyte counts in chronically FeLV-infected cats. Further studies are warranted to evaluate whether administration of DEC could eliminate circulating retroviral-infected cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.